Watch out, oncology drugmakers. Memorial Sloan-Kettering Cancer Center has made a move that could crimp your ambitions for premium pricing. The leading hospital says it will exclude Sanofi's ($SNY) new colorectal cancer drug Zaltrap from its treament protocols--because its price is twice as high as competing treatments, but has proven no more effective than its rivals, namely Roche's ($RHHBY) Avastin.
Novartis' ($NVS) vaccine business is hanging in the balance, relying on the potential approval of a shot to protect against a meningitis-causing bacteria to keep the unit afloat.
Will Abraxane join the new gang of melanoma fighters?
Will Abraxane join the new gang of melanoma fighters? The Celgene ($CELG) drug, a reformulated version of the chemo drug paclitaxel, kept the cancer at bay for longer than the standard chemotherapy, dacarbazine, a new study found.
Drug development is a tough business. Sometimes, just when you think you're getting to the pot at the end of the rainbow, you find the trap door one step away. It's not supposed to work that...
2012 has seen some of the biggest failures in the history of drug R&D.
Click here to see my top 5 flops of the year >>
If a drug brand is suddenly worth less, then pieces of that brand are worth less, too. Perhaps so much less that they're no longer worth the effort. That appears to be the rationale for Bristol-Myers Squibb and Sanofi's revamped agreement on the bloodthinner Plavix and blood-pressure remedy Avapro.
Johnson & Johnson ($JNJ), Eli Lilly ($LLY) and Boehringer Ingelheim touted new late-stage data supporting their experimental diabetes drugs, part of the SGLT2 class.
When Abbott Laboratories ($ABT) came up with the made-up name, AbbVie, for its pharmaceutical spinoff, there was a fair amount of ridicule. Now critics can have fun with the potentially mixed-up credentials of Richard Gonzalez, who was selected to lead it.
Bristol-Myers Squibb and partner Pfizer have a new target date for FDA action on their bid to gain U.S. approval of their blockbuster hopeful Eliquis (apixaban). The agency has accepted the companies' resubmission of an NDA after twice delaying approval of the anti-clotting drug, with a new expected decision date of March 17, 2013.